Egrifta (Tesamorelin) Online: Cost, Candidacy, and What the Evidence Shows

What Is Egrifta (Tesamorelin) and What Is It FDA-Approved For?

Tesamorelin, sold under the brand Egrifta SV, is a synthetic analog of growth hormone-releasing hormone (GHRH). It stimulates the pituitary gland to release the body's own growth hormone rather than replacing it directly. The FDA approved it specifically for reducing excess visceral adipose tissue in adults with HIV-associated lipodystrophy [1].

Mechanism of Action

Tesamorelin binds GHRH receptors on the anterior pituitary, prompting a pulsatile rise in endogenous growth hormone. That, in turn, raises insulin-like growth factor 1 (IGF-1). The downstream effect studied in trials is a reduction in visceral fat mass, the metabolically active fat that surrounds abdominal organs and correlates with cardiometabolic risk [1].

FDA-Approved Indication vs. Off-Label Use

The approved indication is narrow. It covers HIV-positive adults with lipodystrophy and excess abdominal fat, a condition tied to antiretroviral therapy and chronic HIV infection itself [4]. Some telehealth clinics prescribe tesamorelin off-label for general body recomposition or anti-aging purposes. That use is not backed by the same trial data, and insurance will not cover it outside the approved indication.

Who Is a Candidate for Tesamorelin?

The best candidates are HIV-positive adults with confirmed visceral fat accumulation, stable antiretroviral therapy, and no active pituitary disease or cancer history. A provider typically confirms candidacy using body composition imaging or waist circumference plus a clinical exam, not symptoms alone.

Good-Candidate Profile

Adults with HIV lipodystrophy, elevated waist-to-hip ratio, and normal baseline IGF-1 tend to respond best in the trial population studied by Falutz and colleagues [1]. Patients without HIV can request tesamorelin, but they fall outside the FDA label, meaning any prescription would be off-label and evidence for that group is thinner.

Contraindications and Precautions

Tesamorelin is contraindicated in patients with active malignancy, pituitary gland disruption from prior surgery or radiation, or known hypersensitivity to the drug. It should not be used during pregnancy. Providers also screen for disrupted hypothalamic-pituitary-adrenal axis function before starting therapy, since GHRH analogs depend on an intact pituitary response.

Quick self-check before booking a telehealth visit:

1. Do you have a confirmed HIV diagnosis with visible or measured abdominal fat accumulation?
2. Are you currently stable on antiretroviral therapy for at least 8 weeks?
3. Do you have any history of pituitary tumor, active cancer, or uncontrolled diabetes?
4. Are you pregnant, breastfeeding, or planning pregnancy in the near term?
5. Have you had recent IGF-1 or fasting glucose labs within the past 6 months?

If you answered yes to 1 and 2, and no to 3 and 4, you likely meet the basic screening bar a telehealth provider will apply. Question 5 determines whether new labs get ordered before the first prescription.

What Does the Clinical Evidence Show?

Two identically designed 26-week randomized, placebo-controlled trials, pooled and reported by Falutz and colleagues in the New England Journal of Medicine, remain the core evidence base for tesamorelin. Tesamorelin reduced visceral adipose tissue by roughly 15% from baseline, while the placebo group saw little to no reduction over the same period [1].

Key 26-Week Trials

The pooled trial population included hundreds of HIV-positive adults with lipodystrophy. Tesamorelin also raised IGF-1 levels into the high-normal range, consistent with its GHRH mechanism, without causing clinically significant glucose disturbance in most participants during the treatment window [1]. Quality of life and trunk fat measures also moved favorably compared with placebo.

Long-Term Data and Durability

A follow-up analysis by the same research group examined what happens when treatment continues beyond the initial 26 weeks or stops. Visceral fat reduction was largely maintained with continued dosing, and much of the benefit reversed within months after discontinuation, supporting the idea that tesamorelin manages a chronic condition rather than curing it [2]. This durability pattern is why most prescribers treat it as an ongoing therapy, not a short course.

Figure spec (bar chart, for design team): X-axis categories: "Tesamorelin, 26 weeks" and "Placebo, 26 weeks." Y-axis: percent change in visceral adipose tissue from baseline. Bar values: Tesamorelin approximately -15%, Placebo approximately 0%, sourced from [1]. Second panel, monthly cost comparison bar chart: "Brand list price ~$3,500," "Cash-pay average ~$3,500," "Compounded average ~$350," sourced from internal HealthRX pricing data referenced in this article.

How Much Does Egrifta (Tesamorelin) Cost?

Brand-name Egrifta SV lists around $3,500 per month, and cash-pay pricing at most pharmacies lands near that same figure absent insurance coverage. Compounded tesamorelin from compounding pharmacies averages closer to $350 per month, a substantial difference that comes with tradeoffs in regulatory oversight and quality assurance.

Brand List Price vs. Cash Pay

Insurance coverage for Egrifta SV depends heavily on confirmed HIV-associated lipodystrophy diagnosis codes. Patients using it off-label for general fat loss or anti-aging purposes should expect to pay cash, since payers rarely cover indications outside the FDA label. Manufacturer patient-assistance programs exist for eligible HIV patients and can meaningfully lower out-of-pocket cost, though eligibility rules change periodically.

Compounded Tesamorelin: Pros, Cons, and Legality

Compounded tesamorelin is not an FDA-approved product. It is prepared by compounding pharmacies under different regulatory pathways than commercially manufactured Egrifta SV, meaning batch-to-batch purity and dosing accuracy are not independently verified by the FDA the way an approved drug is [3]. The lower price reflects that reduced oversight, not necessarily equivalent quality. Patients choosing compounded versions should ask their pharmacy for a certificate of analysis and confirm the pharmacy holds proper state licensure.

How to Get Egrifta (Tesamorelin) Online

Getting a tesamorelin prescription online generally takes a video or asynchronous intake visit, a review of HIV status and current medications, and in many cases a request for recent labs including IGF-1 and fasting glucose. Most licensed telehealth platforms can complete initial screening within a day or two, with prescriptions sent to a pharmacy once a provider signs off.

Step-by-Step Online Visit

A typical online visit starts with an intake form covering HIV diagnosis history, antiretroviral regimen, and body composition concerns. A licensed provider then reviews the intake, may request a video consult, and orders labs if none exist within the past six months. Once results come back within acceptable ranges, the provider issues the prescription, which routes electronically to either a standard or compounding pharmacy depending on the patient's choice and eligibility.

What Providers Check Before Prescribing

Before writing a prescription, a provider confirms there is no active malignancy, no untreated pituitary disorder, and no pregnancy. They also check baseline IGF-1 and fasting glucose, since GHRH analogs can shift glucose metabolism in some patients. Ongoing care typically includes a recheck of IGF-1 around three months into treatment to confirm the dose is producing an appropriate physiologic response without overshooting normal ranges.

Do You Need a Prescription? Safety, Side Effects, and Monitoring

Yes. Tesamorelin is a prescription-only injectable medication in the United States, and no legitimate pharmacy dispenses it without a valid prescription from a licensed provider. Side effects reported in trials were generally mild to moderate, with injection-site reactions and joint pain among the most common complaints [1].

Common Side Effects

Reported side effects from the key trials include injection-site erythema or pruritus, arthralgia, peripheral edema, and myalgia [1]. Elevated IGF-1 beyond the normal range can occur and is one reason providers recheck labs periodically rather than treating tesamorelin as a start-and-forget therapy.

Monitoring Plan

A reasonable monitoring plan includes IGF-1 at baseline and around week 12, fasting glucose at baseline and periodically thereafter, and a clinical check-in on injection-site tolerance. Patients with diabetes or prediabetes warrant closer glucose monitoring given the growth-hormone-mediated effects on insulin sensitivity described in the trial safety data [1][2].

Anyone weighing whether tesamorelin fits their situation can review candidacy criteria and current pricing in more detail through HealthRX's tesamorelin program page, where a licensed clinician evaluates HIV status, labs, and goals before any prescription is written.